Language selection


Tylvalosin (TYLV) - Medicating Ingredient Brochure

Status: Veterinary prescription required for approved claims

Date of revision: April 2018

Table of approved species and claims
Approved livestock species Approved claim(s)
(abbreviated) Table Note 1
Withdrawal time Name of approved brand(s)
  1. Treatment of Porcine Proliferative Enteropathy
0 days Aivlosin 17%
Tylvalosin Medicated Premix

Table Notes

Table Note 1

In order to be compliant with the Feeds Regulations, the complete claim must appear on the medicated feed label.

Return to table note 1  referrer


Table of approved claims and brands
Approved claims Name of approved brand(s) Drug concentration in DIN product
Claim 1 Aivlosin 17%
Tylvalosin Medicated Premix
(as tylvalosin tartrate) at
170 g/kg

Claim 1

For the treatment of Porcine Proliferative Enteropathy (PPE) associated with Lawsonia intracellularis in pigs.

Level of medicating ingredient in a complete feed

42.5 mg/kg (0.00425%) tylvalosin in the complete feed.

Directions for use in a complete feed

This livestock feed contains a medically important antibiotic. To reduce the development of antimicrobial resistance and maintain effectiveness, use this antibiotic prudently.

Feed this medicated feed as the sole ration for 14 consecutive days.

Additional information (not to appear on feed labels)

For feed manufacturers

Add and thoroughly mix into the ration at the following rate to provide 42.5 mg/kg (0.00425%) tylvalosin per metric tonne (1000 kg) of finished (complete) feed:


To aid in the even distribution of drug in the finished feed, add full amount of Aivlosin 17% into a small portion of the feed (at least 10 kg per tonne of finished feed) and mix. Blend this mixture into the remainder of the feed and mix thoroughly.


  1. No withdrawal period is required when this medicated feed is fed at the recommended level of 42.5 mg/kg (0.00425%) tylvalosin in the complete feed.
  2. Tylvalosin has been shown to cause hypersensitivity reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin tartrate should avoid contact with this product. When mixing and handling tylvalosin, avoid inhalation, oral exposure and direct contact with skin or eyes. (Required on premix and supplement labels only)
  3. Keep out of reach of children. (Required on premix and supplement labels only)


  1. Not for use in breeding animals.
  2. The effects of tylvalosin on male and female reproductive performance, including pregnancy and lactation, have not been determined.
  3. Do not use in feeds containing pellet binding agents with the exception of Lignosol (4%) and Agri-Colloid (0.3%). (Required on premix and supplement labels only)
  4. Do not use in feeds containing bentonite. (Required on premix and supplement labels only)
  5. Acute cases and severely diseased pigs with reduced food and water intake should be treated with a suitable injectable product.
  6. It is sound clinical practice to base treatment on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria.
  7. Use of the product deviating from the instructions may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with other macrolides due to the potential for cross-resistance.

Accepted Compatibilities


Date modified: